Opinion|Videos|September 23, 2024
Long-term Safety of JAK Inhibitors in Atopic Dermatitis
Key Takeaways
- Long-term upadacitinib data reveal sustained efficacy and safety, offering insights beyond short-term studies for atopic dermatitis management.
- Comparisons with other JAK inhibitors highlight differences in long-term outcomes, influencing clinical decision-making.
Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Are there any learnings from long-term upadacitinib data that were not seen in short-term data?
- What about short vs long-term data with other JAKi?
- How do they impact your use of JAKi for atopic dermatitis?
Advertisement
Related to this article
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
Advertisement
Advertisement
Trending on HCPLive
1
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
5 Gastroenterology Headlines You Missed in September 2026
4
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
5